Aktienanalyse zu 60 Degrees Pharmaceuticals Inc (SXTP)SXTP60 Degrees Pharmaceuticals Inc

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Given the current price of $0.59, a 71.43% year-to-date decline, and an RSI of 22.83 indicating oversold conditions, SXTP is not a good buy right now. The company's financials show a net loss of $2.26 million in Q2 2026, and the stock is trading significantly below its 52-week high of $8.62, reflecting weak market sentiment and ongoing financial struggles.